---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003574"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:25:20.793364+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience appoints John Duke to board; incentive share pool increases 3.9M

## Summary
- John Duke appointed to board effective June 2, 2025; will serve on audit and nominating committees.
- Thomas Loewald resigned from board effective May 30, 2025; no disagreement cited.
- Katherine Eade named Lead Independent Director.
- Shareholders approved Amended and Restated 2021 Incentive Plan, increasing authorized shares by 3,923,000.
- Non-binding advisory vote on executive compensation passed with 23.8M for vs 2.5M against.

## SEC filing metadata
- accession: 0001171843-25-003574
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/f8k_060225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003574
- JSON: https://secwatch.observer/filing/0001171843-25-003574.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003574.txt

## Key facts
- Executive change
  John D. Duke was appointed as Director at HARVARD BIOSCIENCE INC.
  - Action: appointed
  - Role: Director
  source text: On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm
- Executive change
  Thomas Loewald resigned as Director at HARVARD BIOSCIENCE INC.
  - Action: resigned
  - Role: Director
  source text: On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm
- Executive change
  Katherine Eade was appointed as Lead Independent Director at HARVARD BIOSCIENCE INC.
  - Action: appointed
  - Role: Lead Independent Director
  source text: One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.